Sight Sciences, Inc. has announced groundbreaking results from multiple clinical studies validating the long-term effectiveness of its OMNI® Surgical System in treating glaucoma. The comprehensive data will be presented at the upcoming 2025 American Glaucoma Society Annual Meeting.
A landmark meta-analysis encompassing 22 studies has demonstrated the OMNI® Surgical System's ability to achieve significant and sustained reductions in intraocular pressure (IOP) while decreasing patients' reliance on medications. This extensive review represents the most comprehensive evaluation of the technology to date.
Real-world evidence from the American Academy of Ophthalmology's IRIS® Registry has further substantiated these findings. The 36-month study, which stands as the largest evaluation of standalone canaloplasty and trabeculotomy procedures, showed maintained IOP reductions and decreased medication requirements in patients with primary open-angle glaucoma.
Clinical Efficacy Across Disease Severity
The ROMEO Study analysis, published in Clinical Ophthalmology, revealed that the OMNI® system delivers consistent benefits regardless of disease severity. The data demonstrated equivalent effectiveness in lowering IOP and reducing medication usage across mild, moderate, and advanced glaucoma cases – a crucial finding for clinicians managing patients across the disease spectrum.
Surgical Innovation in Glaucoma Management
The OMNI® Surgical System represents a significant advancement in minimally invasive glaucoma surgery (MIGS). The technology combines two established procedures – canaloplasty and trabeculotomy – in a single platform, addressing multiple points of resistance in the conventional outflow pathway.
"These comprehensive clinical outcomes validate OMNI's position as a versatile and effective surgical option for glaucoma patients," said Paul Badawi, CEO of Sight Sciences. "The sustained benefits observed across different disease stages particularly highlight the technology's potential to transform the treatment paradigm."
Future Implications
The robust clinical evidence supporting the OMNI® Surgical System suggests a promising future for glaucoma treatment. With demonstrated efficacy across disease severities and sustained long-term outcomes, the technology offers physicians a valuable tool in their surgical armamentarium for managing this sight-threatening condition.
